linjc16/ctgov huggingface dataset:
Evaluation of Pancreatobiliary Disorders in Patients With Altered Gastric Anatomy

Study Overview
=================
Brief Summary
-----------------
In patients, who have altered gastric anatomy and pancreatobiliary disease, the use of an endoscopic overtube to facilitate an Endoscopic Retrograde Cholangiopancreatography (ERCP).

Official Title
-----------------
Prospective Evaluation of Clinical Utility of Endoscopic Retrograde Cholangiopancreatography (ERCP) With Overtube in Patients With Altered Gastric Anatomy

Conditions
-----------------
Pancreatobiliary Disease, Altered Gastric Anatomy

Intervention / Treatment
-----------------
* Procedure: Endoscopic Retrograde Cholangiopancreatography (ERCP)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subject is 18 years or older Subject has medical indication for Endoscopic Retrograde Cholangiopancreatography (ERCP) Subject has altered gastric anatomy Subject must be able to give informed consent. Exclusion Criteria: Any contraindication for Endoscopic Retrograde Cholangiopancreatography (ERCP) with overtube The subject is unable to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Pancreatobiliary disease<br>Patients who have altered gastric anatomy who need an ERCP with an overtube for evaluation of pancreatobiliary disease. | Procedure: Endoscopic Retrograde Cholangiopancreatography (ERCP)<br>* An Endoscopic Retrograde Cholangiopancreatography (ERCP) performed with an overtube in the evaluation of pancreatobiliary disease in patients with altered gastric anatomy<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Papilla or Duct-enterostomy Was Reached |  | During procedure, up to 3 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Successful Cannulation of the Duct of Intent | Deep cannulation of the bile/pancreatic duct was indicated in 12 of 13 ERCPs, one procedure was performed for stent removal only. This outcome was only relevant when deep cannulation was clinically indicated, therefore this outcome was determined out of 12 ERCPs. | During procedure, up to 3 hours | 
| Successful Endoscopic Therapy |  | During procedure, up to 3 hours | 
| Total Procedure Time |  | During procedure, up to 3 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pancreatobiliary disease in patients with altered gastric anatomy.
Investigation of Clinical Relevance of β-D-Glucan Tests in Patients With Invasive Fungal Infection (IFI)

Study Overview
=================
Brief Summary
-----------------
Invasive fungal infection (IFI) is a disease usually occurred in the patients with compromised immune condition, such as acute leukemia, allogeneic stem cell transplantation or long term immune suppression treatment with the incidence increasing over last decades. Given the introduction of numerous anti-fungal agents and great advance has been made in recent years, IFI is still a dangerous disease with high mortality. Early diagnosis of IFI is still a problem challenging the physicians. Serum tests of β-D-Glucan are introduced to the diagnosis of IFI, which have the advantage of easy application. However, the value of this test in the monitoring of antifungal treatment remains unclear. The investigators perform this study to evaluate the correlation of the serum test results of β-D-Glucan test with the treatment response during the anti-fungal treatment, and hope to see that the results of serial serum tests are good predictive markers for treatment response.

Detailed Description
-----------------
This is a single center, open-label study. The duration of the study will be 2 years. The number of targeted subjects will be 50 (in 2 years). We estimate that on average, the treatment duration is 4-8 weeks. Serum Glucan levels will be measured 2 times per week until the recovery of the infection or treatment end.

Official Title
-----------------
Investigation of the Clinical Relevance of Serial Concentrations of β-D-Glucan Tests in the Patients With Invasive Fungal Infection

Conditions
-----------------
Fungal Infection

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with proven or probable IFI and immunocompromised because of hematopoietic-cell transplantation (HSCT) or chemotherapy, and have positive results for serum Glucan tests will be included in the study. Patients must satisfy all the following criteria before entering the study : Episode of proven or probable IFI, diagnosed according to the EORTC/MSG definitions; Immunocompromised because of HSCT or chemotherapy for malignant hematopathy; ≥ 2 consecutive positive serum glucan level, using a threshold for positivity of ≥ 60 ng/L, at the start of antifungal therapy. Exclusion Criteria: If the fungal infection of the patient is excluded or confirmed to be a specific pathogen other than fungi before the enrollment/during the study period, he or she will be excluded/withdrew from the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
IFI, β-D-Glucan test
Comparison of the Radiological Pattern Between the Cerebral Stroke of Arterial and Venous Origin

Study Overview
=================
Brief Summary
-----------------
There are few published data on the patterns of parenchymal imaging abnormalities in a context of cerebral venous thrombosis (CVT). The objectives of the present study were to describe the patterns of parenchymal lesions associated with CVT and to determine the lesion sites.

Official Title
-----------------
Comparison of the Radiological Pattern Between the Cerebral Stroke of Arterial and Venous Origin

Conditions
-----------------
Stroke, Superior Sagittal Sinus Thrombosis, Venous Thromboses

Intervention / Treatment
-----------------
* Other: radiological comparison


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: hospitalized patients with CVT parenchymal lesions on magnetic resonance imaging Exclusion Criteria: No CVT

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| hemorrhagic ischemia<br>comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging) | Other: radiological comparison<br>* comparison between clinical and radiological characteristics<br>|
| nonhemorrhagic ischemia<br>comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging) | Other: radiological comparison<br>* comparison between clinical and radiological characteristics<br>|
| intracerebral hematoma<br>comparison between clinical characteristics and the confirmed diagnosis by RMI (magnetic resonance Imaging) | Other: radiological comparison<br>* comparison between clinical and radiological characteristics<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patterns | describe the patterns of parenchymal lesions associated with CVT and to determine the lesion sites. | 0 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
RMI
Applications of Dual-Energy Computed Tomography

Study Overview
=================
Brief Summary
-----------------
The purpose of the study is to evaluate the feasibility of multilayer detection-based dual energy computed tomography scanner and to assess the added diagnostic value of dual energy applications

Official Title
-----------------
Applications of Dual-Energy Computed Tomography

Conditions
-----------------
Other Conditions That May Be A Focus of Clinical Attention

Intervention / Treatment
-----------------
* Device: Computed Tomography scan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male or female subject Subjects with relative clinical findings indicative for CT examination. CT referral request approved by a physician is needed Voluntary signed the Informed Consent Form Exclusion Criteria: Pregnant or potentially pregnant female subjects Subjects who are not able or not willing to give written Informed Consent without a caregiver consent
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Computed Tomography scan|Routine Computed Tomography scan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Capability of producing dual energy computed tomography imaging and dual energy applications |  | 6 months |
A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of Imrecoxib in the treatment of patients with knee osteoarthritis.

Official Title
-----------------
A Multicenter，Open-label Phase Ⅳ Trial of Imrecoxib in Treatment of Knee Osteoarthritis

Conditions
-----------------
Knee Osteoarthritis

Intervention / Treatment
-----------------
* Drug: Imrecoxib


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged form 18 years to 75 years old Diagnosed with osteoarthritis of the knee according to the American College of Rheumatology Functional capacity class of Ⅰ-Ⅲ Exclusion Criteria: Unstable angina History of myocardial infarction within the last 6 months Stroke in the 6 months before screening New York Heart Association class Ⅲ-Ⅳ congestive heart-failure Systolic blood pressure>180mmHg,and/or Diastolic blood pressure>100mmHg Peptic ulcer Known contraindications to non-steroidal anti-inflammatory drug（NSAID） Received aspirin within 3 days of baseline visit Aspirin dosage>150mg/d Known to be Allergic to sulfa and COX-2 inhibitors Pregnancy or lactation Glutamic-oxaloacetic transaminase and/or glutamic-pyruvic transaminase>2 times upper limit of normal Blood urine nitrogen>1.5 times upper limit of normal

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Imrecoxib<br>0.1g,BID,po | Drug: Imrecoxib<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline in Patient's Assessment of Arthritis Pain, according to Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)3.0 |  | Baseline to Week 24 | 
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability |  | Baseline to week 24 |
Study on Effects of a Dairy Product Based on Polyphenols and Enriched With Vitamins B6, B9 and B12 on Some Cardiovascular Factor of Risk

Study Overview
=================
Brief Summary
-----------------
We put forward that polyphenols and vitamins have a cardiovascular prevention effect for subject with cardiovascular risk.

Conditions
-----------------
Cardiovascular Risk Factors

Intervention / Treatment
-----------------
* Dietary Supplement: Vitamins B6, B9 and B12 and polyphenols
* Dietary Supplement: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: BMI less than 33 kg/m² Waist measurement higher than 90 cm for woman and 100 cm for man Normal or controled blood pressure (less than 16/9) non-smoker Female with contraception Exclusion Criteria: Food allergy Cardiovascular pathology Medical treatment for cholesterol Higher consumption for dairy product and red fruit

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 74 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>Female with active product | Dietary Supplement: Vitamins B6, B9 and B12 and polyphenols<br> <br> |
| Active Comparator: 2<br>Male with active product | Dietary Supplement: Vitamins B6, B9 and B12 and polyphenols<br> <br> |
| Placebo Comparator: 3<br>Female with placebo | Dietary Supplement: placebo<br> <br> |
| Placebo Comparator: 4<br>Male with placebo | Dietary Supplement: placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Reduction of cardiovascular factor of risk
Establishment of Ideal IV Sedative Regimen for Successful Fiberoptic Bronchoscopy in Assessing the Site, Severity of Sleep Apnea Syndrome

Study Overview
=================
Brief Summary
-----------------
Venous thromboembolism(VTE) is the third most common cardiovascular complication among hospitalized patients, and can even cause death. VTE often occurs in intensive care patients and there had been many efforts to prevent such complication. The American College of Chest Physicians (ACCP) had published evidence-based clinical practice guideline for VTE prophylaxis. This study focuses on how VTE prophylaxis is being performed in both medical and surgical ICUs in a single University hospital, and sees the differences in such prophylactic patterns.

Conditions
-----------------
Sleep Apnea Syndrome

Intervention / Treatment
-----------------
* Drug: dexmedetomidine infusion rate, 0.5 mcg/kg/hr
* Drug: dexmedetomidine infusion rate, 1.0 mcg/kg/hr


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 20-60 years old patients with ASA class I-II Scheduled for drug induced sleep endoscope after diagnosed with sleep apnea syndrome Exclusion Criteria: Patients having hearing difficulties, taking any CNS related medication, history of any adverse drug reaction, Glasgow coma scale < 15 Patients with severe cardiopulmonary dysfunction Patients refusal

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: dexmedetomidine 0.5 mcg/kg/hr<br> | Drug: dexmedetomidine infusion rate, 0.5 mcg/kg/hr<br>* continuous infusion of dexmedetomidine at rate of 0.5 mcg/kg/hr<br>|
| Active Comparator: dexmedetomidine 1.0 mcg/kg/hr<br> | Drug: dexmedetomidine infusion rate, 1.0 mcg/kg/hr<br>* continuous infusion of dexmedetomidine at rate of 1.0 mcg/kg/hr<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Desaturation rate | SpO2 < 90% (checked by pulse oximetry) | Baseline from 5 min after remifentanil TCI start, 10 min after dexmedetomidine loading start, every 5 min until surgeon can do endoscopy successfully, to immediately after endoscopy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
sleep apnea syndrome, fiberoptic bronchoscopy, IV sedation
Acute Effects of Acu-Transcutaneous Electrical Nerve Stimulation (Acu-TENS) on Forced Expiratory Flow Volume in One Second (FEV1) and Blood β-Endorphin Level in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to investigate the effectiveness of Acu-TENS (transcutaneous electrical nerve stimulation applied on acupoints) on lung functions, dyspnoeic symptoms and its association with beta endorphin level in subjects with COPD.

Official Title
-----------------
Acute Effects of Acu-TENS on FEV1 and Blood β-Endorphin Level in Subjects With COPD

Conditions
-----------------
Chronic Obstructive Pulmonary Disease (COPD)

Intervention / Treatment
-----------------
* Device: Transcutaneous electrical nerve stimulation (TENS)
* Device: Transcutaneous electrical nerve stimulation (TENS)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: clinical diagnosis with COPD Exclusion Criteria: allergic to gel unable to perform spirometry unable to communicate

Ages Eligible for Study
-----------------
Minimum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Group 1<br>Application of Acu-TENS | Device: Transcutaneous electrical nerve stimulation (TENS)<br> <br> |
| Placebo Comparator: Group 2<br> | Device: Transcutaneous electrical nerve stimulation (TENS)<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Forced expiratory flow volume in one second (FEV1), forced vital capacity (FVC) |  | measured before and after intervention | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Beta endorphin |  | before and after intervention | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
COPD, FEV1, beta endorphin, TENS, acupuncture
Evaluation of Accuvein in Adult Patients

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to evaluate the effectiveness of Accuvein to facilitate venous blood sampling and placement of peripheral intravenous catheters in adults. This clinical protocol is designed to determine whether using Accuvein increases the ease and efficiency of venous cannulation (as perceived by the operator), decreases the time to effective cannulation, decreases the number of sticks, and decreases the patient's perception of the pain.

Official Title
-----------------
Evaluation of Accuvein for Blood Sampling and for Intravenous Catheter Placement in Adult Patients

Conditions
-----------------
Catheterization

Intervention / Treatment
-----------------
* Device: Accuvein
* Device: Accuvein


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: adults requiring a venous blood sampling or the placement of a venous peripheral catheter Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Venous blood sampling<br>To use Accuvein to improve the effectiveness of venous blood sampling | Device: Accuvein<br>* Accuvein will be used to facilitate venous blood sampling<br>|
| Experimental: Peripheral IV catheter placement<br>To use Accuvein to improve the effectiveness of placing peripheral IV catheter | Device: Accuvein<br>* Accuvein will be used to facilitate peripheral IV catheter placement<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time to successful blood sampling or to successful placement of IV catheter |  | one hour | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of attempts required |  | Immediately after attempts | 
| Pain |  | Immediately after attempts | 
| Increases in the ease and efficiency of venous cannulation perceived by the operator) |  | Immediately after attempts |